Four NextGenNK partners join forces in a Phase II study in Multiple Myeloma
XNK Therapeutics AB (“XNK”) has entered into a joint Phase II clinical study to treat patients with multiple myeloma using XNK’s drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa (isatuximab)
The investigator initiated Phase II study is made possible by four parties’ engagement in the trial. XNK will provide its novel autologous NK cell-based product for the study, set to take place at the Karolinska University Hospital in Stockholm, Sweden. XNK, Sanofi, and Karolinska University Hospital are all collaborative partners within NextGenNK, which is coordinated by Karolinska Institutet.
“Performing this Phase II study together with Karolinska Institutet is an important step for XNK in its ambition to combat multiple myeloma,” said Johan Liwing, CEO of XNK Therapeutics. “Combining our efforts together with the present partners highlights just how far XNK has progressed with its patented technology platform.”
The study, ISA-HC-NK (EudraCT: 2020-000994-26), compares XNK’s drug candidate combined with isatuximab against isatuximab as a consolidation treatment following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma.